Stereospecific synthesis of m-Hydroxymexiletine enantiomers

Drug Metabolism Letters

Volumn 6, Issue 3, 2012, Pages 182-186

  Catalano, Alessia ^a   Carocci, Alessia ^a   Lentini, Giovanni ^a   Defrenza, Ivana ^a   Bruno, Claudio ^a   Franchini, Carlo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Anti arrhythmics; Asymmetric synthesis; Chirality; M Hydroxymexiletine; Sodium channel blockers

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA CYCLODEXTRIN; DRUG METABOLITE; META HYDROXYMEXILETINE; MEXILETINE; SODIUM; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CAPILLARY ELECTROPHORESIS; CHIRALITY; DECHLORINATION; DRUG HYDROXYLATION; DRUG SYNTHESIS; ENANTIOMER; NITRATION; PRIORITY JOURNAL; STEREOSPECIFICITY; SULFATION;

BETA-CYCLODEXTRINS; ELECTROPHORESIS, CAPILLARY; MEXILETINE; STEREOISOMERISM; SULFATES; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84876739258     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312811206030005     Document Type: Article

References (34)

1. Tucker, G.T. Chiral switches. Lancet, 2000, 355, 1085-1087.
2. Ito, T.; Ando H.; Handa, H. Teratogenic effects of thalidomide: molecular mechanisms. Cell. Mol. Life Sci., 2011, 68, 1569-1579.
3. McBride, W.G. Thalidomide embryopathy. Teratology, 1977, 16, 79-82.
4. Lenz, W. A short history of thalidomide embryopathy. Teratology, 1988, 38, 203-215.
5. Brown, J.M.; Davies, S.G. Chemical asymmetric synthesis. Nature, 1989, 342, 631-636.
6. Sloan, P.; Basta, M.; Storey, P.; von Gunten, C. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. Anesth. Analg., 1999, 89, 760-761.
7. Jarvis, B.; Coukell, A.J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs, 1998, 56, 691-707.
8. Oskarsson, P.; Ljiunggren, J.-G.; Lins, P.-E. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care, 1997, 20, 1594-1597.
9. Tremont-Lukats, I.W.; Challapalli, V.; McNicol, E.D.; Lau, J.; Carr, D.B. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth. Analg., 2005, 101, 1738-1749.
10. Rüdel, R.; Lehmann-Horn, F. Membrane changes in cells from myotonia patiens. Physiol. Rev., 1985, 65, 310-356.
11. Lehmann-Horn, F.; Jurkat-Rott, K. Voltage-gated ion channels and hereditary disease. Physiol. Rev., 1999, 79, 1317-1372.
12. Cannon, S.C. Voltage-gated ion channelophaties of the nervous system. Clin. Neurosci. Res., 2001, 1, 104-117.
13. Gay, S.; Dupuis, D.; Faivre, L.; Masurel-Paulet, A.; Labenne, M.; Colombani, M.; Soichot, P.; Huet, F.; Hainque, B.; Sternberg, D.; Fontaine, B.; Gouyon, J.-B.; Thuvin-Robinet, C. Severe neonatal nondistrophic myotonic secondary to a novel mutation of the voltage-gated sodium channel (SCN4A) gene. Am. J. Med. Genet. A., 2008, 146A, 380-383.
14. Akinci, E.; Yüzbaşioglu, Y.; Coşkun, F. Hemodialysis as an alternative treatment of mexiletine intoxication. Am. J. Emerg. Med., 2011, 29, 1235-1236.
15. Catalano, A.; Desaphy, J.-F.; Lentini, G.; Carocci, A.; Di Mola, A.; Bruno, C.; Carbonara, R.; De Palma, A.; Budriesi, R.; Ghelardini, C.; Perrone, M.G.; Colabufo, N.A.; Conte Camerino, D.; Franchini, C. Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels. J. Med. Chem., 2012, 55, 1418-1422.
16. Desaphy, J.-F.; Dipalma, A.; Costanza, T.; Carbonara, R.; Di Nardo, M.M., Catalano, A.; Carocci, A.; Lentini, G.; Franchini, C.; Conte Camerino, D. Molecular insights into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine. Front. Pharmacol., 2012, 3, 1-12.
17. Catalano, A.; Carocci, A.; Lentini, G.; Defrenza, I.; Cavalluzzi, M.M.; Franchini, C. An improved synthesis of m-hydroxymexiletine, a potent mexiletine metabolite. Drug Metab. Lett., 2012, 6, 124-128.
18. Labbé, L.; Turgeon, J. Clinical Pharmacokinetics of Mexiletine. Clin. Pharmacokinetic., 1999, 37, 361-384.
19. Hill, R.J.; Duff, H.J.; Sheldon, R.S. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. Mol. Pharmacol., 1988, 34, 659-663.
20. De Luca, A.; Natuzzi, F.; Lentini, G.; Franchini, C.; Tortorella, V., Conte Camerino, D. Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers. Naunyn-Schmiedebergs Arch. Pharmacol., 1995, 352, 653-661.
21. + channels. J. Med. Chem., 2003, 46, 5238-5248.
22. De Luca, A.; Natuzzi, F.; Desaphy, J.-F.; Loni, G.; Lentini, G.; Franchini, C.; Tortorella, V.; Conte Camerino, D. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels. Mol. Pharmacol., 2000, 57, 268-277.
23. Catalano, A.; Carocci, A.; Corbo, F.; Franchini, C.; Muraglia, M.; Scilimati, A.; De Bellis, M.; De Luca, A.; Conte Camerino, D.; Sinicropi, M.S.; Tortorella, V. Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents. Eur. J. Med. Chem., 2008, 43, 2923-2925.
24. Carocci, A.; Catalano, A.; Corbo, F.; Duranti, A.; Amoroso, R.; Franchini, C.; Lentini, G.; Tortorella, V. Stereospecific synthesis of mexiletine and related compounds: Mitsunobu versus Williamson reaction. Tetrahedron: Asymmetry, 2000, 11, 3619-3634.
25. Pascale, R.; Carocci, A.; Catalano, A.; Lentini, G.; Spagnoletta, A.; Cavalluzzi, M.M.; De Santis, F.; De Palma, A.; Scalera, V.; Franchini, C. New N-(phenoxydecyl)phthalimide derivatives displaying potent inhibition activity towards α-glucosidase. Bioorg. Med. Chem., 2010, 18, 5903-5914.
26. Màtyus, P.; Rettegi, T.; Varrò, A.; Papp, J.G. New antiarrhythmic agents: a conceptually novel approach. Med. Res. Rev., 2000, 20, 294-303.
27. Anwer, M.K.; Sherman, D.B.; Roney, J.G.; Spatola, A.F. Applications of ammonium formate catalytic transfer hydrogenation. 6. Analysis of catalyst, donor quantity, and solvent effects upon the efficacy of dechlorination. J. Org. Chem., 1989, 54, 1284-1289.
28. Franklin, R.; Golding, B.T.; Tyson, R.G. Mexiletine amino acid and peptide prodrugs and uses thereof. W.O. Patent 2012149760, December 29, 2010.
29. Catalano, A.; Carocci, A.; Fracchiolla, G.; Franchini, C.; Lentini, G.; Tortorella, V.; De Luca, A.; De Bellis, M.; Desaphy, J.-F.; Conte Camerino, D. Stereospecific synthesis of para-hydroxymexiletine and sodium channel blocking activity evaluation. Chirality, 2004, 16, 72-78.
30. Vandamme, N.; Broly, F.; Libersa, C.; Courseau, C.; Lhermitte, M. Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6 - a preliminary report. J. Cardiovasc. Pharmacol., 1993, 21, 77-83.
31. Cavalluzzi, M.M.; Catalano, A.; Bruno, C.; Lovece, A.; Carocci, A.; Corbo, F.; Franchini, C.; Lentini, G.; Tortorella, V. Synthesis of (R)-, (S)-, and (RS)-hydroxymethylmexiletine, one of the major metabolites of mexiletine. Tetrahedron: Asymmetry, 2007, 18, 2409-2417.
32. 1H NMR chiral solvating agents. Tetrahedron: Asymmetry, 2009, 20, 1984-1991.
33. Yu, L.; Hong, Y.; Li, L.; Jin, Y.; Zheng, M.; Jiang, H.; Zeng, S. Enantioselective drug-protein interaction between mexiletine and plasma protein. J. Pharm. Pharmacol., 2004, 64, 792-801.
34. Shi, D.; Jin, Y.; Tang, Y.; Hu, H.; Xu, S.; Yu, L.; Jiang, H.; Zeng, S. Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains. Acta Pharmacol. Sin., 2012, 33, 710-716.